Strategies for dosing and switching antipsychotics for optimal clinical management

Journal of Clinical Psychiatry

Volumn 69, Issue SUPPL. 1, 2008, Pages 4-17

  Buckley, Peter F ^a   Correll, Christoph U ^b,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; HALOPERIDOL; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE; PROLACTIN;

AGITATION; AKATHISIA; ANHEDONIA; ANTICHOLINERGIC EFFECT; BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; METABOLIC DISORDER; MOOD DISORDER; MOTIVATION; PARKINSONISM; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOEDUCATION; QUALITY OF LIFE; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ADULT; BLOOD; CASE REPORT; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RISK FACTOR; WITHDRAWAL SYNDROME;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 45749095939     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
2. Mahmoud RA, Engelhart LM, Janagap CC, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin Drug Investig 2004;24:275-286
3. Sohler NL, Walkup J, McAlpine D, et al. Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia. Psychiatr Serv 2003;54:1258-1263
4. Diaz FJ, de Leon J. Excessive antipsychotic dosing in 2 US state hospitals. J Clin Psychiatry 2002;63:998-1003
5. Owen RR, Fischer EP, Kirchner JE, et al. Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. Am J Med Qual 2003;18:140-146
6. Preskorn SH. Relating clinical trials to psychiatric practice, pt 2. The gap between the usual patient in registration trials and in practice. J Psychiatr Pract 2003;9:455-461
7. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006;84:77-89
8. Correll CU. Real-life dosing with second-generation antipsychotics. J Clin Psychiatry 2005;66:1610-1611
9. Zyprexa (olanzapine). Physicians' Desk Reference. 61st ed. Montvale, NJ: Thomson; 2007
10. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090-2095
11. Citrome L, Jaffe A, Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatr Serv 2007;58:11
12. Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 2005;25:388-391
13. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136
14. Weiden PJ, Preskorn SH, Fahnestock P, et al. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmap. J Clin Psychiatry 2007;68(suppl 7):3-46
15. de Leon J, Susce MT, Pan RM. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27
16. de Leon J, Susce MT, Murray-Charmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 2006;10:135-151
17. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000;34:200-207
18. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005;7:121-129
19. Zarate CA, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161:169-171
20. Aguglia E, De Vanna M, Onor ML, et al. Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1229-1233
21. Lindenmayer JP, Czobor P, Volavka J, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry 2002;63:931-935
22. Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 2004;9:357-364
23. Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003;18:432-440
24. Weiden PJ, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64:580-588
25. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610
26. De Nayer A, Windhager E, Irmansyah, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003;7:59-66
27. Lang DJ, Kopala LC, Vandorpe RA, et al. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry 2004;161:1829-1836
28. Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-1089
29. van Os J, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004;19:229-232
30. Cook PE, Goldberg JO, Van Lieshout RJ. Benefit of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Can J Psychiatry 2002;47:870-874
31. Kaneda Y, Kawamura I, Fujii A, et al. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia. Neuro Endocrinol Lett 2004;25:135-140
32. Nakajima M, Terao T, Iwata N, et al. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Pharmacopsychiatry 2005;38:17-19
33. Bartko G, Trixler M, Bitter I, et al. Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics [in Hungarian]. Neuropsychopharmacol Hung 2006;8:201-209
34. De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophrenia Bull 2007;33:823-830
35. Meyer JM, Pandina G, Bossie CA, et al. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005;27:1930-1941
36. Montes JM, Rodriguez JL, Balbo E, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:383-388
37. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056
38. Ried LD, Renner BT, Bengtson MA, et al. Weight change after an atypical antipsychotic switch. Ann Pharmacother 2003;37:1381-1386
39. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl) 2005;183:383-386
40. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 2007;68(suppl 1):12-19
41. Casey DE, Carson WH, Saha AR, et al, for the Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391-399
42. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690
43. Kujawa M, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment of schizophrenia. Int J Neuropsychopharmacol 2002;5(suppl 1):S186
44. Kujawa M, Stock E, Carson WH, et al. Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder [poster]. Presented at the 23rd Collegium Internationale Neuro-Psychopharmacologicum Congress; June 23-27, 2002; Montreal, Quebec, Canada
45. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
46. Bourin M, Auby P, Swanink R, et al. Aripiprazole vs haloperidol for maintained treatment effect in acute mania [poster]. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif
47. Cornblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole vs olanzapine in stable psychosis. Int J Neuropsychopharmacol 2002;5(suppl 1):S185-S186
48. Weiden PJ. Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 2006;20:104-118
49. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24
50. Hanssens L, L'Italien G, Marcus RN, et al. Sexual dysfunction in a naturalistic open label study of aripiprazole and standard of care in the management of community-treated schizophrenic patients [poster]. Presented at the 159th annual meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Ontario, Canada
51. L'Italien G, Hanssens L, Marcus RN, et al. Metabolic effects of aripiprazole versus standard of care (the STAR trial) [poster]. Presented at the 159th annual meeting of the American Psychiatric Association; May 20-25, 2006; Toronto, Ontario, Canada
52. Kim SF, Huang AS, Snowman AM, et al. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007;104:3456-3459
53. Pfizer Inc. Briefing Document for Zeldox Capsules (ziprasidone HCl). Submitted to FDA Psychopharmacological Drugs Advisory Committee; July 19, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf. Accessed Dec 15, 2006
54. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(suppl 18):47-56
55. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone [published online ahead of print 18 July 2007]. Neuropsychopharmacology. doi: 10.1038/sj.npp. 1301482
56. Marcus RN, Newcomer JW, Carson WH, et al. A large, multicenter, randomized, double-blind study of the effects of aripiprazole in overweight patients with schizophrenia/schizoaffective disorder switched from olanzapine [poster]. Presented at the 11th International Congress on Schizophrenia Research; March 28-April 1, 2007; Colorado Springs, Colo
57. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 2007;68(suppl 6):10-13
58. Remington G, Chue P, Stip E, et al. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 2005;76:2-3
59. Correll CU. Real-life switching strategies with second-generation antipsychotics [American Society of Clinical Psychopharmacology Corner]. J Clin Psychiatry 2006;67:160-161
60. Casey DE, Daniel DG, Wassef AA, et al. Effect of dival-proex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003;28:182-192